Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 3 | -$0.66 | -$0.47 | -$0.57 |
Q2 2025 | 2 | -$1.22 | $0.05 | -$0.58 |
Q3 2025 | 2 | -$1.35 | $0.06 | -$0.64 |
Q4 2025 | 2 | -$1.45 | $0.06 | -$0.69 |
EyePoint Pharmaceuticals, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.54 earnings per share for the quarter, missing analysts' consensus estimates of $-0.48 by $0.06. The company had revenue of 10.52 M for the quarter and had revenue of 46.02 M for the year. EyePoint Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-1.82 diluted earnings per share) and currently has a price-to-earnings ratio of -3.79. EyePoint Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/07/2024 | Q3 2024 | -$0.48 | -$0.54 | -0.06 | $10.40 M | $10.52 M |
08/08/2024 | Q2 2024 | -$0.58 | $10.63 M | $9.48 M | ||
03/30/2024 | Q1 2024 | -$0.55 | $11.68 M | |||
12/30/2023 | Q4 2023 | -$0.33 | $14.03 M | |||
11/03/2023 | Q3 2023 | -$0.33 | $7.86 M | $15.20 M | ||
08/04/2023 | Q2 2023 | -$0.61 | $79.10 M | $9.11 M | ||
05/04/2023 | Q1 2023 | -$0.58 | $7.68 M | |||
03/10/2023 | Q4 2022 | -$1.72 | $10.53 M | |||
11/04/2022 | Q3 2022 | -$0.49 | $10.93 M | $10.01 M | ||
08/05/2022 | Q2 2022 | -$0.52 | $10.86 M | $11.57 M | ||
05/06/2022 | Q1 2022 | -$0.60 | $9.29 M | |||
03/11/2022 | Q4 2021 | -$0.59 | $11.54 M | |||
11/05/2021 | Q3 2021 | -$0.58 | $9.88 M | $9.06 M | ||
08/06/2021 | Q2 2021 | -$0.35 | $8.71 M | $9.01 M | ||
05/05/2021 | Q1 2021 | -$0.53 | -$0.50 | 0.03 | $7.32 M | |
03/12/2021 | Q4 2020 | -$1.07 | $7.13 M | |||
11/06/2020 | Q3 2020 | -$0.30 | $13.32 M | $15.70 M | ||
08/05/2020 | Q2 2020 | -$1.10 | -$1.04 | 0.06 | $3.79 M | $4.12 M |
05/08/2020 | Q1 2020 | -$1.14 | $7.49 M | |||
03/16/2020 | Q4 2019 | -$0.98 | $8.63 M |
EyePoint Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based off last year's report dates.
The conference call for EyePoint Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for EyePoint Pharmaceuticals, Inc.'s latest earnings report can be read online.
EyePoint Pharmaceuticals, Inc. (:EYPT) has a recorded annual revenue of $46.02 M.
EyePoint Pharmaceuticals, Inc. (:EYPT) has a recorded net income of $46.02 M. EyePoint Pharmaceuticals, Inc. has generated $-1.82 earnings per share over the last four quarters.
EyePoint Pharmaceuticals, Inc. (:EYPT) has a price-to-earnings ratio of -3.79 and price/earnings-to-growth ratio is 0.32.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED